Indonesia Dermatology Drugs Market Analysis Report [2022-30] I Insights10

Indonesia Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Indonesia Dermatology drugs market will reach a value of $xx Mn from $102 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as PT Sanbe Farma, PT Kimia Farma (Persero) Tbk, and PT Kalbe Farma Tbk. The market is driven by the increasing prevalence of dermatological diseases, awareness about dermatological health, and government regulations. The dermatology drug market in Indonesia is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10IDPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Vishwa Modhia

Buy Now

Indonesia Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Indonesia Dermatology drugs market will reach a value of $xx Mn from $102 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

As of November 2021, 62% of people in Indonesia had enlarged pores, the most common skin problem that they experienced, followed by acne and comedones. In Indonesia, hospitals and medical trade shows are excellent places to look for potential local partners for the dermatology drug business.

According to WHO data published in 2020, 3,734 deaths from skin diseases, or 0.22% of all deaths, occurred in Indonesia. Indonesia is ranked 75th in the world with an age-adjusted death rate of 1.90 per 100,000 people. In 2019, only 2.9% of Indonesia's GDP was spent on healthcare, despite the fact that Indonesia has one of the largest and fastest-growing economies in Southeast Asia.

Market Dynamics

Market Growth Drivers

Pharmaceutical companies are spending money on research and development to produce cutting-edge dermatology drugs that will increase consumer demand. Indonesia, which is home to the fourth-largest population in the world, presents a huge market for drug and device exporters. In 2014, the Indonesian government launched an online system (e-Katalog) for purchasing medical items that would be covered by the country's public health insurance program.

The prevalence of skin conditions like acne, eczema, and psoriasis is increasing in Indonesia, which is increasing the demand for dermatology drugs. This is due to rising pollution levels, changing lifestyles, and increased awareness of skin care.

Market Restraints

Even though the national health insurance program (Jaminan Kesehatan Nasional) is expanding, not all Indonesian citizens have access to insurance, which for some patients may restrict their access to dermatology medications. It's possible that access to healthcare facilities is restricted in some parts of Indonesia, which can make it challenging for patients to obtain dermatology medications and other treatments.

Competitive Landscape

Key Players

PT Kalbe Farma Tbk (IDN)
PT Kimia Farma (Persero) Tbk (IDN)
PT Sanbe Farma (IDN)
PT Pharmasi Inti Corpindo (IDN)
PT Dexa Medica (IDN)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Indonesian National Agency of Drug and Food Control (BPOM) is the organization in charge of regulating dermatology medications in Indonesia. Prior to being marketed and sold in Indonesia, dermatology medications are among the drugs and medical devices for which the BPOM is in charge of ensuring safety, effectiveness, and quality. To make sure that only safe and efficient products are offered to consumers, this includes carrying out pre-market evaluations, post-market surveillance, and enforcing regulations.

Depending on the type of medication and the patient's insurance coverage, the reimbursement status for dermatology medications in Indonesia may change. For those who qualify, Indonesia's Jaminan Kesehatan Nasional (JKN) national health insurance program will pay a portion of the cost of medications, including dermatology medications. The specific drug, the patient's insurance coverage, and other factors can affect how much is reimbursed under the JKN program.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.